Persistence Paved the Path of Discovery for an Immunotherapy Pioneer
October 8th 2018Thomas F. Gajewski, MD, PhD, has made inroads in the field of cancer immunotherapy, most notably discovering the connections between the microbiome and clinical outcomes—findings that will enable the creation of microbiota-modulating interventions to improve outcomes in patients undergoing cancer treatments.
Read More
Debating the True Benefit of Adjuvant TKIs in High-Risk RCC
October 4th 2017Adjuvant therapy with tyrosine kinase inhibitors for patients with high-risk renal cell carcinoma (RCC) who have undergone a nephrectomy may be supported by level IIa evidence from the National Comprehensive Cancer Network guidelines.
Read More
Identifying Actionable Biomarkers Crucial to Advancing Precision Medicine in MBC
July 28th 2017While several biomarkers have been identified in patients with breast cancer, including ESR1 and PIK3CA mutations, not all of these are driver mutations that can be effectively targeted with treatment.
Read More
Trastuzumab Combos, Novel Agents Key to Advancing HER2+ Breast Cancer Care
July 28th 2017Experts are trying to determine whether combination regimens with additional HER2-directed therapies or alternative therapies could improve responses in HER2-positive breast cancer without added toxicities.
Read More
Function of IDH Mutations Can Be Exploited by PARP Inhibitors Instead of IDH Inhibitors
April 4th 2017A phase II basket trial has been announced to test that mutations in isocitrate dehydrogenase 1 and 2 are not driver mutations that should be targeted with direct IDH inhibitors, but instead they create vulnerabilities that can be exploited through treatment with PARP inhibitors.
Read More
Prevalence of Ph-like ALL in Adults Emphasizes Need for Targeted Clinical Trials
February 12th 2017A recent study published in the Journal of Clinical Oncology has found that Philadelphia chromosome-like acute lymphoblastic leukemia (ALL) accounts for over 20% of all adult patients with ALL and is correlated with poor outcomes.
Read More
Lancet Data Highlight OS Benefit for Regorafenib in HCC
December 9th 2016Regorafenib (Stivarga) has demonstrated the first survival benefit for a systemic therapy in the second-line setting for patients with advanced hepatocellular carcinoma (HCC) who have progressed on sorafenib (Nexavar), according to results from the phase III RESORCE trial published in The Lancet.1
Read More
No Clinical Benefit With Adjuvant Ibandronate in Postmenopausal Breast Cancer
December 9th 2016Adjuvant ibandronate (Boniva) added to hormone therapy did not provide a clinical benefit to postmenopausal patients with HR-positive, early-stage breast cancer, according to findings from the phase III TEAM IIB trial.
Read More
Everolimus Added to Fulvestrant Doubles PFS in HR+ Breast Cancer
December 7th 2016The addition of everolimus (Afinitor) to fulvestrant (Faslodex) significantly improved progression-free survival rates in postmenopausal patients with metastatic hormone receptor–positive, HER2-negative breast cancer who are resistant to aromatase inhibitor therapy.
Read More
Dual Biomarker Signature Holds Predictive Promise for Response to Anti-PD-L1 Therapy in NSCLC
November 16th 2016Recent research suggests that the presence of PD-L1–positive and CD8+ cells may be useful for predicting responses in patients with non-small cell lung cancer who have been treated with durvalumab.
Read More
Expert Emphasizes Lack of Treatment Options for Medullary Thyroid Cancer
October 20th 2016Though some patients with medullary thyroid cancer can live with their disease without progression for long periods of time, the majority will eventually enter a phase in which their cancer becomes much more aggressive.
Read More
Expert Sheds Light on Identifying "Lynch-Like Syndrome" in Patients With dMMR Rectal Cancer
October 12th 2016To properly manage patients with DNA mismatch repair deficiency rectal cancer, one must have a well-rounded understanding of the molecular and clinical causes and risks associated with this subgroup of patients.
Read More
5 Key Areas in Emerging Immunotherapy Research Stand Out
September 24th 2016Although checkpoint blockade inhibitors targeting the PD-1/PD-L1 pathway are currently dominating the oncology community's attention, there are many other exciting approaches to anticancer immunotherapy being explored in a range of solid tumors
Read More
Leptomeningeal Metastases More Common in EGFR-Mutant NSCLC
August 22nd 2016In patients with EGFR-mutant non–small cell lung cancer, the incidence of leptomeningeal metastases is found to be common; moreover, the optimal treatment for this occurrence was determined to be tyrosine kinase inhibitors.
Read More
Low Recurrence Score in Breast Cancer Shows No Survival Benefit With Chemo Plus Hormonal Therapy
July 28th 2016Collective findings from clinical trials show that, for women with early-stage breast cancer who have a low 21-gene recurrence score, adding chemotherapy to standard hormonal therapy does not show a difference in survival.
Read More
Possible Biomarker Could Determine Risk of Colon Cancer Recurrence
July 15th 2016A liquid biopsy test of circulating tumor DNA for residual disease may be able to determine the risk of recurrence for patients with stage II colon cancer beyond radiologic tests and clinicopathological risk features.
Read More
Study Calls for Basing Lung Cancer Screening Guidelines on Individual Risk
May 26th 2016An individualized, risk-based approach to screening current and former smokers for the early detection of lung cancer would dramatically expand the population that could benefit from the preventive strategy, while saving more lives than the current US Preventive Services Task Force guidelines for lung cancer screening.
Read More
IHC Staining Found Effective for ROS1+ NSCLC
May 22nd 2016The use of immunohistochemistry could be a more cost- and time-efficient first-line screening method for identifying ROS1 gene rearrangements to predict eligibility for crizotinib (Xalkori) for patients with non–small cell lung cancer compared with fluorescence in-situ hybridization.
Read More